Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. raised its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 313,238 shares of the company’s stock after acquiring an additional 22,400 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $5,645,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. UMB Bank n.a. raised its stake in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares during the last quarter. Smithfield Trust Co grew its holdings in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares in the last quarter. Byrne Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $52,000. Claro Advisors LLC acquired a new position in Teva Pharmaceutical Industries during the third quarter worth about $52,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at about $57,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 1.8 %

NYSE TEVA opened at $16.50 on Friday. Teva Pharmaceutical Industries Limited has a 12 month low of $9.90 and a 12 month high of $19.31. The stock has a market capitalization of $18.69 billion, a P/E ratio of -19.41, a PEG ratio of 1.04 and a beta of 0.79. The firm’s 50-day moving average is $17.51 and its two-hundred day moving average is $17.39. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on TEVA shares. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Barclays lifted their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. UBS Group raised their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.67.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.